NO20076102L - Ny behandling og/eller forhindring av kreft og/eller artritt - Google Patents

Ny behandling og/eller forhindring av kreft og/eller artritt

Info

Publication number
NO20076102L
NO20076102L NO20076102A NO20076102A NO20076102L NO 20076102 L NO20076102 L NO 20076102L NO 20076102 A NO20076102 A NO 20076102A NO 20076102 A NO20076102 A NO 20076102A NO 20076102 L NO20076102 L NO 20076102L
Authority
NO
Norway
Prior art keywords
cancer
prevention
arthritis
new treatment
treatment
Prior art date
Application number
NO20076102A
Other languages
English (en)
Inventor
Christine Power
Melanie Yorke-Smith
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of NO20076102L publication Critical patent/NO20076102L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Oppfinnelsen angår anvendelse av INSP I 63 til behandling og/eller forhindring av kreft og/eller muskelskvamøs/bindevevslidelse, særlig lungekreft og/eller osteoartritt. Kombinasjoner av INSP163 med et interferon, en TNF-antagonist eller ytterligere anti-kreft eller anti-artrittmiddel er også innenfor foreliggende oppfinnelse.
NO20076102A 2005-04-26 2007-11-26 Ny behandling og/eller forhindring av kreft og/eller artritt NO20076102L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05103402 2005-04-26
US68173105P 2005-05-17 2005-05-17
PCT/EP2006/061710 WO2006114387A2 (en) 2005-04-26 2006-04-20 Insp163 polypeptides for the treatment or prevention of cancer and arthritis

Publications (1)

Publication Number Publication Date
NO20076102L true NO20076102L (no) 2008-01-25

Family

ID=36889295

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076102A NO20076102L (no) 2005-04-26 2007-11-26 Ny behandling og/eller forhindring av kreft og/eller artritt

Country Status (8)

Country Link
US (1) US20100303760A9 (no)
EP (1) EP1879611B1 (no)
JP (1) JP2008539194A (no)
AU (1) AU2006239405B2 (no)
CA (1) CA2603671C (no)
IL (1) IL186754A0 (no)
NO (1) NO20076102L (no)
WO (1) WO2006114387A2 (no)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
GEP20002142B (en) 1991-01-18 2000-06-25 Amgen Inc Method for Treatment and Prevention of TNF Mediated Diseases
US6193963B1 (en) * 1996-10-17 2001-02-27 The Regents Of The University Of California Method of treating tumor-bearing patients with human plasma hyaluronidase
CN1452633A (zh) * 2000-09-08 2003-10-29 先灵公司 哺乳动物基因、相关试剂及方法
WO2003031586A2 (en) * 2001-10-12 2003-04-17 Human Genome Sciences Inc. Acrp30-like polynucleotides, polypeptides, and antibodies
GB0325038D0 (en) * 2003-10-27 2003-12-03 Ares Trading Sa Protein

Also Published As

Publication number Publication date
WO2006114387A3 (en) 2007-05-10
IL186754A0 (en) 2008-02-09
JP2008539194A (ja) 2008-11-13
AU2006239405A1 (en) 2006-11-02
EP1879611B1 (en) 2011-10-26
AU2006239405B2 (en) 2011-12-08
US20100303760A9 (en) 2010-12-02
EP1879611A2 (en) 2008-01-23
US20090035274A1 (en) 2009-02-05
WO2006114387A2 (en) 2006-11-02
CA2603671A1 (en) 2006-11-02
CA2603671C (en) 2012-03-27

Similar Documents

Publication Publication Date Title
CY1116156T1 (el) Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο
CL2008003407A1 (es) Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
TW200510416A (en) P38 inhibitors and methods of use thereof
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ZA200500966B (en) Biphasic composition induced by polydextrose and sucrose
IN2005DE03350A (no)
MXPA05011523A (es) Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas.
AU2003272285A8 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
TW200505904A (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
MXPA05013016A (es) Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.
ATE426409T1 (de) Antitumor-kombinationen mit vegf-trap und 5fu oder einem seiner derivate
MX2007007206A (es) Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos.
WO2005123113A3 (en) Interferon compositions and methods of use thereof
WO2006128120A3 (en) Novel lapachone compounds and methods of use thereof
NO20076102L (no) Ny behandling og/eller forhindring av kreft og/eller artritt
IL197769A (en) The history of morphine, medicinal preparations containing them and their use in the preparation of pain medication
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
WO2007012066A3 (en) TRUNCATED OXIDIZED THYMOSIN β4 AND DERIVATIVES THEREOF
BRPI0419229A (pt) derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica
TW200509918A (en) Treatment of depression and other affective disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application